Objectives. Main objective is to verify the value of implantable loop recorder (ILR) in assessing the mechanism of syncope and the efficacy of the ILR-guided therapy after syncope recurrence. Inclusion criteria. Patients who met the following criteria are included: suspected or definite neurally mediated syncope based on initial evaluation; ≥3 syncope episodes in the last 2 years; severe clinical presentation of syncope requiring treatment initiation in the judgement of the investigator and age >30 years. Exclusion criteria. Patients with one or more of the following are excluded: carotid sinus syndrome; suspected or definite heart disease and high likelihood of cardiac syncope; symptomatic orthostatic hypotension diagnosed by standing blood pressure measurement; loss of consciousness different from syncope (e.g. epilepsy, psychiatric, metabolic, drop-attack, TIA, intoxication, cataplexy) and subclavian steal syndrome. End-points. The primary end-points are the ECG-documented syncopal events and the syncope recurrences after application of ILR-guided therapy. Sample size and duration. A minimum of 400 patients will be enrolled during an anticipated period of 3 years.
- Electrocardigraphic monitoring
- Implantable loop recorder
- Neurally mediated syncope